A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Anastasi, Federica
• dc.contributor.author Fernández-Lebrero, Aida
• dc.contributor.author Ortiz Romero, Paula, 1994-
• dc.contributor.author Torres-Torronteras, Javier
• dc.contributor.author González Escalante, Armand
• dc.contributor.author Contador, Jose
• dc.contributor.author García Escobar, Greta
• dc.contributor.author Manero, Rosa María
• dc.contributor.author Navalpotro-Gómez, Irene
• dc.contributor.author Jiménez-Moyano, Esther
• dc.contributor.author Grau-Rivera, Oriol
• dc.contributor.author Campo, Marta del
• dc.contributor.author Puig-Pijoan, Albert
• dc.contributor.author Suárez-Calvet, Marc
• dc.date.accessioned 2025-05-14T06:00:51Z
• dc.date.available 2025-05-14T06:00:51Z
• dc.date.issued 2025
• dc.description.abstract Introduction: Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited. Methods: In this cross-sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort (Hospital del Mar, Barcelona) were analyzed. Participants were classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed the ability of plasma p-tau181, p-tau217, p-tau231, t-tau, and Aβ42/40 to classify Aβ pathology status. Results: Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting Aβ pathology. Among them, plasma p-tau217 consistently outperformed the others, demonstrating superior area under the curves. Furthermore, p-tau217 showed the strongest correlation between plasma and CSF levels, underscoring its potential as a reliable surrogate for CSF biomarkers. Discussion: Several plasma biomarkers, targeting different epitopes and using different platforms, demonstrated high performance in detecting AD in a memory clinic setting. Highlights: Plasma p-tau biomarkers demonstrated higher diagnostic performance and larger effect sizes than t-tau and Aβ42/40 assays in detecting Alzheimer's disease. Among the p-tau biomarkers, p-tau217 assays consistently outperformed the others, providing superior classification of Aβ pathology status across different phosphorylation sites. p-tau217 assays showed the strongest correlation between plasma and CSF levels, indicating its potential as a reliable surrogate for CSF biomarkers. Several plasma p-tau biomarkers can be used in a specialized memory clinic to accurately detect Alzheimer's disease.
• dc.description.sponsorship Federica Anastasi receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. Henrik Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). Marc Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through the project SLD077/21/000001; Project “PI19/00155″ and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).
• dc.format.mimetype application/pdf
• dc.identifier.citation Anastasi F, Fernández-Lebrero A, Ashton NJ, Ortiz-Romero P, Torres-Torronteras J, González-Escalante A, et al. A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic. Alzheimers Dement. 2025 Feb;21(2):e14609. DOI: 10.1002/alz.14609
• dc.identifier.doi http://dx.doi.org/10.1002/alz.14609
• dc.identifier.issn 1552-5260
• dc.identifier.uri http://hdl.handle.net/10230/70380
• dc.language.iso eng
• dc.publisher Wiley
• dc.relation.ispartof Alzheimers Dement. 2025 Feb;21(2):e14609
• dc.relation.projectID info:eu-repo/grantAgreement/EC/HE/101053962
• dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/948677
• dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/847648
• dc.rights © 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword Alzheimer's disease
• dc.subject.keyword Amyloid‐β
• dc.subject.keyword Biomarker
• dc.subject.keyword Diagnosis
• dc.subject.keyword Phosphorylated tau
• dc.subject.keyword Plasma
• dc.title A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion